Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

12%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Phase 1

13(76.5%)

Phase 2

2(11.8%)

Phase 3

2(11.8%)

17Total

Phase 1(13)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT07449156Phase 1Not Yet Recruiting

A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.

Role: lead

NCT07383116Phase 3Not Yet Recruiting

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Role: lead

NCT07360132Phase 3Not Yet Recruiting

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Role: lead

NCT06895499Phase 1Recruiting

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

Role: lead

NCT06612970Phase 1Recruiting

A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants

Role: lead

NCT06999083Phase 1Recruiting

A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants

Role: lead

NCT06992687Phase 1Enrolling By Invitation

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors